Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.51 |
| ▸ | DRD2 | P14416 | 4/20 | 0.54 |
| ▸ | HTR1A | P08908 | 3/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6591284 | 0.95 | DRD2 (0.59) | DRD2HTR1ASLC6A4 | |
| Oxalic Acid SCHEMBL6776147 | 0.91 | HTR1D (0.51) | DRD2HTR1AHTR1DKDM4EALOX15 | |
| SCHEMBL6589336 | 0.88 | DRD2 (0.59) | DRD2HTR1ASLC6A4 | |
| SCHEMBL6587179 | 0.85 | HTR1D (0.49) | DRD2HTR1ASLC6A4HTR1D | |
| SCHEMBL6594841 | 0.80 | HTR1A (0.68) | DRD2HTR1ASLC6A4 | |
| SCHEMBL7538107 | 0.78 | HTR1A (0.52) | DRD2HTR1ASLC6A4 | |
| SCHEMBL6589659 | 0.77 | HTR1D (0.45) | DRD2HTR1ASLC6A4HTR1D | |
| SCHEMBL6591122 | 0.77 | HTR1A (0.47) | DRD2HTR1A | |
| Oxalic Acid SCHEMBL6776746 | 0.76 | DRD2 (0.60) | DRD2HTR1A | |
| SCHEMBL6590608 | 0.75 | DRD2 (0.89) | DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1515568-A | Indole and 2,3-indoline derivative, their preparation and application | H.隆德贝克有限公司 | 2004-07-28 | — | — | CN | disclosed |
| CN-1515569-A | Indole and 2,3-indoline derivative, their preparation and application | H.隆德贝克有限公司 | 2004-07-28 | — | — | CN | disclosed |
| US-6727263-B2 | SEROTONINE REUPTAKE INHIBITOR; ANTIDEPRESSANTS; SIDE EFFECT REDUCTION | H. LUNDBECK A/S (DK) | 2004-04-27 | — | — | US | disclosed |
| CN-1127501-C | indole and 2, 3-indoline derivatives, their preparation and use | LUNDBECK & CO AS H (DK) | 2003-11-12 | — | — | CN | disclosed |
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-01-23 | — | — | US | disclosed |
| US-6476035-B1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-11-05 | — | — | US | disclosed |
| CN-1265107-A | indole and 2, 3-indoline derivatives, their preparation and use | LUNDBECK & CO AS H (DK) | 2000-08-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | TPH1, HTR1A, HTR3A | SLC6A4 25/4885DRD2 26/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.